DEBRA HALL: Open Payments
NPI 1619289485 · OLYMPIA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,331 in 71 payments from 13 companies in 2025. Trend: 2023 $270 · 2024 $727 · 2025 $1,331
Food & beverage: $1,331
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $260 |
| ABBVIE INC. | 17 | $202 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $162 |
| Otsuka America Pharmaceutical, Inc. | 7 | $158 |
| Janssen Pharmaceuticals, Inc | 5 | $133 |
| Alkermes, Inc. | 5 | $105 |
| E.R. Squibb & Sons, L.L.C. | 4 | $101 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Braeburn Inc. | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
Products named: VRAYLAR, CAPLYTA, AUSTEDO XR, ARISTADA, COBENFY, REXULTI, SPRAVATO, INVEGA SUSTENNA.
Industry payments across WA — which companies pay providers there.
